SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) — Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an early access program for voxelotor, in Europe and other regions outside the United States, for the treatment of hemolytic anemia in sickle cell disease (SCD) patients ages 12 years and older.
“With no currently approved therapies outside the United States to treat hemolytic anemia in sickle cell disease, the unmet need in this devastating disease is profound,” said Ted W. Love, M.D., president and chief executive officer of GBT. “As part of our deep, long-term commitment to patient access worldwide, we are pleased to initiate this early access program for eligible patients who may benefit from voxelotor.”
A first-in-class oral, once-daily therapy, voxelotor directly inhibits hemoglobin polymerization, the root cause of the sickling and destruction of red blood cells…
